BOSTON and SYDNEY – 10 August 2017 – GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will update investors on 2017 second quarter results as reported on Form 10Q for the period ended June 30, 2017.
The company will host a webcast at 6 pm EDT 14 August 2017 | 8 am AEST 15 August 2017.
Accessing the Webcast:
For those preferring to listen by telephone, please dial-in five minutes prior to the start of the call. Regional dial-in numbers are as follows:
United States (Toll-Free): 877 407 6184
United Kingdom (Toll-Free): 0 800 756 3429
Germany (Toll-Free): 0 800 182 0040
Australia (Toll-Free): 1 800 687 004
International (Toll; charges will apply): 201 389 0877
The transcript for the call will be available on the company’s website shortly following the webcast.
About GI Dynamics
GI Dynamics, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically delivered device approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.